Why Vir Biotechnology (VIR) Stock Fell 7.02% in 10 Minutes on Nov 12, 2026
MoveSurge measured two earlier Vir Biotechnology headlines with an attributed reaction between Aug 14, 2026 and Nov 11, 2026. The largest was +12.77% in 10 minutes, on Oct 14, 2026.
- VIR fell 7.02% in the 10 minutes after the 16:17:53 ET headline, from $11.40 to $10.60.
- 53,740 shares changed hands in those 10 minutes.
- The headline crossed in after-hours trading, 17 minutes after the 4:00 ET close.
16:17:53 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| VIR | 11.40 | 11.40 | 11.40 | 10.60 | 0.00% | -7.02% |
Vir Biotechnology (VIR) shares fell 7.02% in the 10 minutes after this headline reached the MoveSurge news feed at 16:17:53 ET on Thursday, November 12, 2026: “Vir Biotechnology plans an underwritten common-stock offering, with all shares sold by the company and an underwriter option for up to 15% more shares.”
VIR in the first 10 minutes
From a reference price of $11.40 just before the headline, the stock was down 7.02%, at $10.60, after 10 minutes. 53,740 shares changed hands in those 10 minutes. The headline crossed in after-hours trading, 17 minutes after the 4:00 ET close.
Earlier VIR headlines and the measured reaction
MoveSurge measured two earlier Vir Biotechnology headlines with an attributed reaction between Aug 14, 2026 and Nov 11, 2026. The largest was +12.77% in 10 minutes, on Oct 14, 2026.
- Oct 14, 2026, 08:30 ET: “VIR Biotechnology and Gilead Sciences have formed a collaboration and licensing agreement to develop new Pro-Xten® dual-masked T-cell engagers targeting solid tumors.” (+12.77% in 10 minutes)
- Oct 8, 2026, 08:39 ET: “Vir Biotechnology's prostate cancer drug VIR-5500 receives Fast Track designation from the FDA.” (-1.95% in 10 minutes)
Vir Biotechnology at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $2.25 billion (as of Nov 12, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Vir Biotechnology stock on November 12, 2026?
At 16:17:53 ET, this headline crossed: “Vir Biotechnology plans an underwritten common-stock offering, with all shares sold by the company and an underwriter option for up to 15% more shares.” The stock fell 7.02% in the next 10 minutes.
How far did VIR move after the headline?
From $11.40 just before the headline to $10.60 10 minutes later, a -7.02% move.
What else has moved VIR stock recently?
The two largest measured reactions before November 12, 2026: Oct 14, 2026, VIR Biotechnology and Gilead Sciences have formed a collaboration and licensing agreement to develop new Pro-Xten® dual-masked T-cell engagers targeting solid tumors. (+12.77% in 10 minutes); Oct 8, 2026, Vir Biotechnology's prostate cancer drug VIR-5500 receives Fast Track designation from the FDA. (-1.95% in 10 minutes).
Sources
-
VIR headline and measured reaction, Nov 12, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Go live — 7 days for $29 Watch live headlines -- free